KR-20260064804-A - Composition for inhibiting lipofuscin accumulation or removing lipofuscin containing metalloprotease derived from a strain of the genus Chryseobacterium

Abstract

The present disclosure discloses a composition for skin anti-aging, skin brightening, or skin texture improvement comprising a metalloproteinase derived from a strain of the genus Cryseobacterium as an active ingredient, and/or a composition for inhibiting lipofuscin accumulation or removing lipofuscin comprising said metalloproteinase as an active ingredient. The composition provides efficacy for skin anti-aging, skin brightening, or skin texture improvement by inhibiting lipofuscin accumulation or removing lipofuscin, and provides an effect of preventing, improving, or treating diseases caused by lipofuscin accumulation.

Inventors

• 김은미
• 조시영

Assignees

• (주)아모레퍼시픽

Dates

Publication Date

20260508

Application Date

20241029

Claims (11)

1. A composition for skin anti-aging, skin lightening, or skin texture improvement, comprising a metalloprotease derived from a strain of the genus Chryseobacterium as an active ingredient.
2. In Article 1, A composition for skin anti-aging, skin lightening, or skin texture improvement, wherein the strain is a Chryseobacterium camelliae strain.
3. In Article 1, A composition for skin anti-aging, skin lightening, or skin texture improvement, wherein the strain is Chryseobacterium camelliae Dolsongi-HT1, deposit number KCCM11883P.
4. In Article 1, A composition for skin anti-aging, skin lightening, or skin texture improvement, wherein the metalloproteinase above comprises the amino acid sequence of SEQ ID NO. 20 or SEQ ID NO. 22.
5. In Article 1, The above composition is a composition for anti-aging, skin brightening, or skin texture improvement that provides skin anti-aging, skin brightening, or skin texture improvement efficacy by inhibiting lipofuscin accumulation or removing lipofuscin.
6. A composition for inhibiting lipofuscin accumulation or removing lipofuscin, comprising a metalloprotease derived from a strain of the genus Chryseobacterium as an active ingredient.
7. In Paragraph 6, A composition for inhibiting lipofuscin accumulation or removing lipofuscin, wherein the strain is a Chryseobacterium camelliae strain.
8. In Paragraph 6, A composition for inhibiting lipofuscin accumulation or removing lipofuscin, wherein the strain is Chryseobacterium camelliae Dolsongi-HT1, deposit number KCCM11883P.
9. In Paragraph 6, A composition for inhibiting lipofuscin accumulation or removing lipofuscin, wherein the metalloproteinase above comprises the amino acid sequence of SEQ ID NO. 20 or SEQ ID NO. 22.
10. In Paragraph 6, The above composition is a composition for inhibiting lipofuscin accumulation or removing lipofuscin, which prevents, improves, or treats diseases caused by lipofuscin accumulation.
11. In Article 10, A composition for inhibiting lipofuscin accumulation or removing lipofuscin, wherein the disease caused by lipofuscin accumulation comprises one or more selected from the group consisting of sarcopenia, progeria, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), myocardial infarction, age-related macular degeneration, neuronal ceroid lipofuscinoses (NCL), acromegaly, denervation atrophy, and chronic obstructive pulmonary disease (COPD).

Description

Composition for inhibiting lipofuscin accumulation or removing lipofuscin containing metalloprotease derived from a strain of the genus Chryseobacterium The present disclosure discloses a composition for skin anti-aging, skin brightening, skin texture improvement, inhibition of lipofuscin accumulation and/or removal of lipofuscin, comprising a metalloproteinase derived from a strain of the genus Cryseobacterium as an active ingredient. Lipofuscin is a metabolite associated with aging or oxidative stress, existing as a form of insoluble pigment within cells. It is known to be formed as incomplete degradation products accumulate within cells due to oxidative stress and cellular deterioration. The higher the accumulation of lipofuscin within cells, the more cellular function declines and the faster the rate of aging becomes. The hearts of long-lived elderly individuals take on a brownish tint and shrink due to an increase in lipofuscin pigment; this phenomenon is known as cardiac brown atrophy. Similar pigmentation can occur in the liver, known as hepatic brown atrophy. Furthermore, cases of lipofuscin pigment deposition in the heart, liver, and kidneys have been reported in cancer patients or those suffering from wasting diseases such as severe pulmonary tuberculosis for a long time. Meanwhile, the most prominent phenomenon associated with skin aging is pigmentation, such as melasma and age spots, which results from the accumulation of lipofuscin. Consequently, lipofuscin is also referred to as "age spots inside the body." Therefore, inhibiting the production and/or accumulation of lipofuscin to prevent it from accumulating in skin cells is crucial for preventing skin aging. As mentioned above, lipofuscin, which naturally occurs during cellular metabolic processes, accumulates in larger quantities within cells not only with aging but also when cellular function declines or there is repeated exposure to external toxins. Furthermore, accumulated lipofuscin interferes with normal cellular function and accelerates the aging process. Lipofuscin is found not only in skin cells but also in the liver, kidneys, heart muscle, retina, adrenal glands, nerve cells, and ganglion cells; it is known to cause various degenerative diseases when it accumulates in vital organs. For example, if lipofuscin accumulates in heart muscle, it can worsen the condition and lead to myocardial infarction, while accumulation in the retina or nerve cells can cause macular degeneration or Alzheimer's disease. Additionally, if it accumulates in hormone-secreting organs such as the adrenal glands, liver, and pituitary gland, it can cause abnormalities in the metabolic function of bodily hormones, including growth hormone and sex hormones. The presence of lipofuscin in the skin has been regarded as a sign of aging, and research is underway on cosmetic ingredients that help reduce it. However, to date, no cosmetic ingredient is known to directly break down lipofuscin; instead, indirect effects are primarily anticipated through certain components that reduce oxidative stress and promote skin cell regeneration. Figure 1 shows the 16S rDNA partial sequence of the Cryseobacterium camellia rhizome-HT1 strain according to one embodiment. Figure 2 shows the results of the keratin degradation activity evaluation according to one embodiment. Figure 3 shows the results of the lipofuscin removal activity evaluation according to one embodiment. The present disclosure will be described in detail below. In this document, "active ingredient" refers to a component that exhibits the intended activity alone or can exhibit the intended activity in combination with a carrier, etc., which is inactive in itself. In one aspect, the present disclosure provides a composition for skin anti-aging, skin lightening, and/or skin texture improvement, comprising a metalloprotease derived from a strain of the genus Chryseobacterium as an active ingredient. In another aspect, the present disclosure provides a method for anti-aging, skin lightening, and/or skin texture improvement, comprising applying or administering a composition containing an amount of a metalloprotease derived from a strain of the genus Chryseobacterium effective for anti-aging, skin lightening, and/or skin texture improvement to a subject in need thereof. In another aspect, the present disclosure provides a composition comprising a metalloprotease derived from a strain of the genus Chryseobacterium for use in anti-aging, skin lightening, and/or skin texture improvement of the skin. In another aspect, the present disclosure provides the use of a composition comprising a metalloprotease derived from a strain of the genus Chryseobacterium for skin anti-aging, skin lightening, and/or skin texture improvement. In another aspect, the present disclosure provides a use of a composition comprising a metalloprotease derived from a strain of the genus Chryseobacterium in preparing a composition for skin anti-aging, skin